* OLYSIO (simeprevir) 150 mg 28 capsules.
* Each capsule contains:
150 mg simeprevir
* Pharmacodynamic properties:
Pharmacotherapeutic group: Antivirals for systemic use, direct acting antivirals, ATC code: J05AE14.
* Mechanism of action:
Simeprevir is a specific inhibitor of the HCV NS3/4A serine protease, which is essential for viral replication. In a biochemical assay, simeprevir inhibited the proteolytic activity of recombinant genotype 1a and 1b HCV NS3/4A proteases, with median Ki values of 0.5 nM and 1.4 nM, respectively.
OLYSIO is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adult patients.
The recommended dosage of OLYSIO is one capsule of 150 mg once daily for 12 weeks, taken with food.
OLYSIO must not be administered as monotherapy. OLYSIO must be used in combination with other medicinal products for the treatment of CHC.
Combination treatment with peginterferon alfa and ribavirin.
* Oral use.
* Rx only.
* Keep out of the sight and reach of children.
ٍStore in the original packaging in order to protect from light.
* Manufactured by: Janssen-Cilag SpA, Via C. Janssen, 04100 Borgo San Michele, Latina, Italy
Licensed from: Medivir AB
استيراد : شركة جونسون وجونسون
توزيع : المصرية لتجارة الأدوية